Manuel was born in Berlin, Germany. He studied Biotechnology and Molecular Life Science at the University of Lübeck and obtained his M.Sc. degree in 2006. For his doctoral work, Manuel went to the Max Planck Institute of Biochemistry in Martinsried (Germany) and the Biozentrum in Basel (Switzerland), joining the laboratory of Erich A. Nigg. During his PhD, he worked to understand the faithful separation of sister chromatids during mitosis. He graduated in January of 2011 from the University of Basel and went on to join the group of Steven F. Dowdy at the University of California in San Diego, USA. During his postdoctoral studies he became interested in the cell cycle entry decision and demonstrated that the tumor suppressor protein Rb is exclusively mono-phosphorylated by Cdk4/6, regulating Rb’s binding affinity to the E2F family of transcription factors. Simultaneously, he developed a strong interest in the CRISPR/Cas9 and rAAV gene editing technologies and since has established several methods and protocols to efficiently perform targeted gene replacement in human cells. Since December 2015, Manuel is an independent group leader at the Institute of Biochemistry II at the Medical Faculty of the Goethe University Frankfurt, Germany. His laboratory is interested in various aspects of cell cycle entry. In particular, his group aims to use gene editing technologies to dissect unperturbed and malignant cell cycle entry mechanisms. Since July 2016, Manuel Kaulich is the head of the novel established Frankfurt CRISPR/Cas9 Screening Center (FCSC). This platform provides the required technical and bioinformatical expertise to perform single/multiple gene knockouts for functional studies using CRISPR/Cas and/or comprehensive, large scale, genome-wide and hypothesis-driven CRISPR/Cas-based screenings.